Company | Acquired By | Date | Date | Value | Terms/Details |
Acquired** | Or Merged With | Announced | Com- | (M) | |
(Country) | (Country) | pleted | |||
I. COMPLETED MERGERS AND ACQUISITIONS | |||||
BioSeq Inc.* | Boston Biomedica | — | 10/98 | $2 | Boston Biomedica paid $2M to buy |
Inc. (NASDAQ:BBII) | the 81% of BioSeq that it didn't | ||||
already own; it paid $1M in cash and | |||||
issued warrants to buy 0.1M shares of | |||||
Boston Biomedica stock at $2.50 each; | |||||
it also assumed BioSeq's debt of | |||||
$0.73M and exchanged BioSeq options | |||||
for Boston Biomedica options | |||||
Chiroscience | Ascot plc | 8/98 | 9/98 | $50 | Ascot acquired a 30% stake in Chiro- |
Technology Ltd. | (U.K.) | science Technology for $50M in cash; | |||
(subsidiary of | Chiroscience Technology also formed a | ||||
Chiroscience Group | manufacturing alliance with Ascot | ||||
plc; U.K.) | subsidiary Mitchell Cotts Chemicals | ||||
Ltd.; the Ascot shares will bear a pre- | |||||
ferential right to dividends and to pro- | |||||
ceeds on sale of the business (prices | |||||
converted at a rate of £0.6/US$1) | |||||
Clinserve | Phoenix Interna- | — | 11/98 | $2.2 | Phoenix acquired all the outstanding |
Laboratories | tional Life Sciences | shares of Clinserve for 0.32M shares | |||
(Switzerland) | Inc. (Canada) | (C$3.4M; exchange rate C$1.53/US$1) | |||
Coral | HemaCare Corp. | 9/98 | 10/98 | ND | HemaCare acquired all of Coral's |
Therapeutics Inc.* | (OTC Bulletin Board: | assets; details ND | |||
HEMA) | |||||
Research and | UCB Pharma | — | 10/98 | $18 | UCB Pharma signed a license and |
discovery assets of | (subsidiary of | technology asset purchase agreement | |||
CytoMed Inc.* | UCB SA; Belgium) | for CytoMed's research and discovery | |||
assets; UCB acquired rights to allergy | |||||
applications of Cytomed's anti-inflam- | |||||
matory dual function inhibitor com- | |||||
pounds and its pre-development | |||||
research programs in asthma and cen- | |||||
tral nervous system disorders; UCB | |||||
paid $12M for acquired assets; UCB | |||||
will assume ongoing activities assoc- | |||||
iated with acquired assets; CytoMed | |||||
could get $6M in product development | |||||
milestones | |||||
Gamma Biologics | Immucor Inc. | 9/98 | 10/98 | $25 | Immucor acquired all the outstanding |
Inc. (AMEX:GBL) | shares of Gamma Biologics in a cash | ||||
tender offer of $5.40 per share | |||||
GenQuest Inc* | Corixa Corp. | 6/98 | 9/98 | $11.8 | Corixa already held a 17% stake in |
GenQuest and acquired the remainder | |||||
for $11.8M ($4.5M in cash and the | |||||
balance in 1.06M Corixa shares at | |||||
$6.84 per share) | |||||
Glyko Inc. | BioMarin Pharma- | — | 10/98 | $14.5 | Glyko Biomedical spun off BioMarin |
(subsidiary of Glyko | ceutical Inc.* | in 1997 and is its lead investor; now, | |||
Biomedical Ltd.; | BioMarin has bought Glyko Inc. from | ||||
TSE:GBL) | the parent company for $14.5M, con- | ||||
sisting of BioMarin stock and the | |||||
assumption of employee stock options | |||||
by BioMarin; Glyko Biomedical's | |||||
stake in BioMarin increased from | |||||
36% to 41.7% | |||||
Gull Laboratories | Meridian | 9/98 | 11/98 | ND | Gull Laboratories' shareholders get |
Inc. (AMEX:GUL) | Diagnostics Inc. | $2.25 in cash for each common share | |||
Hexagen plc* | Incyte Pharma- | 8/98 | 9/98 | $27.7 | Incyte acquired all of Hexagen's out- |
(U.K.) | ceuticals Inc. | standing stock for $5M in cash and | |||
0.97M shares Incyte stock (at $23.25 | |||||
each, or $22.7M); Incyte also assumed | |||||
Hexagen's stock options; Hexagen will | |||||
become part of Incyte's pharmacogen- | |||||
omics business unit, Incyte Genetics | |||||
ImmunoTherapy | AVI BioPharma | 11/97 | 9/98 | $5.8 | According to the letter of intent (11/97), |
Corp.* | (formerly Anti- | Antivirals was to buy ImmunoTherapy | |||
virals Inc.) | for $24M in stock and warrants; how- | ||||
ever, the definitive agreement stated | |||||
that Antivirals would acquire Immuno- | |||||
Therapy for 2.1M shares and 2.1M | |||||
warrants; on completion of the deal, | |||||
AVI BioPharma's shares closed at | |||||
$2.750, valuing the deal at $5.8M | |||||
Imtix (division of | SangStat Medical | 4/98 | 10/98 | $31 | SangStat acquired Imtix for $31M |
Pasteur Merieux | Corp. | ($10M up front at closing and deferred | |||
Connaught, a mem- | cash payments of $21M over 5 years); | ||||
ber of the Rhone- | Pasteur Merieux gets royalties on sales | ||||
Poulenc Group; | of Imtix products | ||||
France) | |||||
Inflammatics Inc.* | Viragen Inc. | 1/98 | 9/98 | $1 | Companies formed a strategic alliance |
and Viragen acquired a 10% stake in | |||||
Inflammatics for $1M; Viragen has | |||||
option to acquire an 80% stake, depend- | |||||
ing on clinical trial results of Leuko- | |||||
VAX (human white blood cell-derived | |||||
drug for treating rheumatoid arthritis) | |||||
McKnight | Phoenix Inter- | — | 11/98 | $6.3 | Phoenix acquired McKnight and its |
Laboratories GmbH | national Life | subsidiary for 0.87M Phoenix shares | |||
and its subsidiary | Sciences Inc. | (C$9.6M; exchange rate C$1.53/US$1) | |||
IPHAR GmbH | (Canada) | ||||
(Germany) | |||||
Molecular | Amersham | 8/98 | 9/98 | $256 | Amersham Pharmacia Biotech offered |
Dynamics Inc. | Pharmacia Biotech | $20.50 per share for Molecular Dynamics' | |||
Inc. (Sweden; joint | outstanding shares (10.3M undiluted) | ||||
venture between | via cash tender offer; based on fully | ||||
Nycomed Amersham | diluted shares, the transaction is valued | ||||
plc and Pharmacia & | at $256M | ||||
Upjohn Inc.) | |||||
Molecular Tool | Orchid | — | 9/98 | ND | Orchid acquired Molecular Tool; |
(subsidiary of | Biocomputer Inc.* | details ND | |||
GeneScreen Inc.*) | |||||
NanoSystems LLC | Elan Corp. plc | 9/98 | 10/98 | $150 | Elan acquired all assets and liabilities |
(subsidiary of | (Ireland) | of NanoSystems for $150M ($137M in | |||
Eastman Kodak Co.; | cash and the rest in warrants to buy | ||||
NYSE:EK) | Elan common shares); NanoSystems | ||||
will become part of Elan Pharmaceuti- | |||||
cal Technologies | |||||
Neurex Corp. | Elan Corp. plc | 4/98 | 8/98 | $740 | Elan acquired all of Neurex's outstand- |
(Ireland) | ing shares (23.3M) for $31.81 per | ||||
share; each share Neurex was | |||||
exchanged for 0.51 Elan American | |||||
Depositary Share; Neurex will become | |||||
business unit of Elan Pharmaceuticals | |||||
NeXstar Products | SKW Americas | 8/98 | 8/98 | $38.5 | NeXstar renamed its Products Technol- |
Technology (division | Inc. (subsidiary of | ogy division Proligo LLC, then sold | |||
of NeXstar Pharma- | SKW Trostberg AG; | 51% of that division to SKW for $15M | |||
ceuticals Inc.) | Germany) | in cash on closing; it also gets $3M in | |||
guaranteed payments and $20.5M in | |||||
milestones over next 5 years; Proligo | |||||
will manufacture aptamers for NeXstar | |||||
to use in drug discovery and develop- | |||||
ment programs; NeXstar retained | |||||
certain rights to its PASS technology | |||||
OncorMed Inc. | Gene Logic Inc. | 7/98 | 9/98 | $39.1 | Gene Logic acquired OncorMed for 4.85M |
shares of Gene Logic stock in a ratio | |||||
of 0.4673 share Gene Logic for 1 share | |||||
OncorMed; Gene Logic also assumed | |||||
outstanding warrants for OncorMed stock | |||||
Penederm Inc. | Mylan Laboratories | 6/98 | 10/98 | $205 | Mylan acquired Penederm for stock; |
Inc. (NYSE:MYL) | Penederm shareholders got 0.68 share | ||||
Mylan for each share Penederm (valued | |||||
at $21.89 per share to Penederm holders) | |||||
Peptide Immune | Biovector | — | 10/98 | ND | Biovector acquired 80% stake in Pep- |
Ligands* (France) | Therapeutics SA* | tide Immune Ligands; Biovector will | |||
(France) | fund 3-year clinical research program | ||||
as well as additional R&D programs | |||||
Rystan Company | Integra Life- | — | 9/98 | $3.6 | Elan acquired Rystan in 5/98 through |
Inc. (indirect subsid- | Sciences Inc. | its acquisition of GWC Health Inc.; | |||
iary of Elan Corp. plc) | Integra acquired Rystan for stock, 0.8M | ||||
shares ($3.6M) plus warrants for 0.3M | |||||
shares of common stock | |||||
Q.E.D. | Quintiles Trans- | — | 10/98 | ND | Quintiles acquired Q.E.D. in exchange |
International Inc. | national Corp. | for Quintiles stock | |||
Seragen Inc. (OTC | Ligand Pharma- | 5/98 | 8/98 | $67 | Ligand acquired Seragen for $67M in |
Bulletin Board:SRGN) | ceuticals Inc. | cash and stock; it paid $30M on closing | |||
($4M in cash and $26M in Ligand | |||||
stock [1.86M shares at $13.99 each]); | |||||
Ligand will pay an additional $37M in | |||||
cash and/or Ligand stock 6 months | |||||
after FDA approval of Ontak (for | |||||
cutaneous T-cell lymphoma) or on | |||||
8/12/00 (whichever is earlier); if FDA | |||||
hasn't approved product by then, there | |||||
will be no $37M payment; Ligand also | |||||
will acquire assets of Marathon Bio- | |||||
pharmaceuticals LLC for $5M, with | |||||
another $3M 6 months after FDA | |||||
approval of Ontak (both payments in | |||||
cash and/or stock); Ligand can buy | |||||
Marathon until 12/24/98 or on 1/31/99 | |||||
Simirex Inc.* | Quintiles Trans- | — | 10/98 | ND | Quintiles acquired Simirex in exchange |
national Corp. | for Quintiles stock | ||||
Tseng Labs Inc. | Cell Pathways Inc.* | 6/98 | 11/98 | $118.8 | This is a reverse merger, by which Cell |
(NASDAQ:TSNG) | Pathways gained a Nasdaq listing | ||||
(CLPA); Cell Pathways acquired and | |||||
merged with Tseng Labs in exchange | |||||
for 5.5M Cell Pathways shares in a | |||||
ratio of 2.75 Tseng shares for 1 Cell | |||||
Pathways share; Cell Pathways also | |||||
gains $28M in cash from Tseng Labs | |||||
Viropath BV* | Digene Corp. | — | 8/98 | $1.7 | Digene bought all the outstanding |
(the Netherlands) | stock of Viropath in exchange for | ||||
0.18M shares of newly issued stock | |||||
Virus Research | T Cell Sciences | 5/98 | 8/98 | $150 | T Cell Sciences acquired Virus Research |
Institute Inc. | Inc. | in a stock transaction with a ratio of 1.55 | |||
shares of T Cell stock and 0.2 warrant | |||||
(5-year warrant to buy 1 share T Cell | |||||
stock for $6.00) for each share Virus | |||||
Research stock; the new company is | |||||
called Avant Immunotherapeutics Inc. | |||||
(NASDAQ:AVAN); T Cell shareholders own | |||||
66% and Virus Research shareholders | |||||
own 34% of the new company | |||||
II. PENDING MERGERS AND ACQUISITIONS | |||||
BioQuest Inc.* | Genetic Vectors | 8/98 | — | ND | Genetic Vectors will acquire 100% of |
Inc. (OTC Bulletin | BioQuest's stock; definitive merger | ||||
Board:GVEC) | agreement still pending | ||||
Cambridge | Oxford Molecular | 9/98 | 4Q:98E | $21.1 | Oxford will pay a total of $21.1M to |
Combinatorial Ltd. | Group plc | buy the 82% of Cambridge Combina- | |||
(U.K.) | (U.K.) | torial that it doesn't already own; it | |||
will pay $5.1M in cash and the remain- | |||||
der by issuing 12.7M new shares of | |||||
Oxford Molecular; subject to approval | |||||
by shareholders (prices converted at a | |||||
rate of £0.585/US$1) | |||||
CellPro Inc. | Nexell Therapeutics | 9/98 | —— | $3 | Nexell will acquire all of CellPro's |
Inc. (majority-owned | intangible assets (intellectual property, | ||||
by Vimrx Pharma- | patents, antibodies and related cell | ||||
ceuticals Inc. and | banks, research and licensed rights) for | ||||
minority-owned by | $3M in Vimrx stock; Baxter will dis- | ||||
Baxter Healthcare | tribute CellPro's Ceprate kits for lim- | ||||
Corp.) | ited time period as CellPro files for | ||||
bankruptcy; agreements subject to | |||||
approval by bankruptcy court | |||||
Oncology diagnostics | Fujirebio Inc. | 10/98 | 4Q:98E | $37.5M | Fujirebio will pay $37.5M for Cento- |
business of | (Japan) | cor's diagnostics business, including | |||
Centocor Inc. | monoclonal antibody-based immuno- | ||||
assays for detecting and monitoring | |||||
solid tumor cancers | |||||
Chiron Diagnostics | Diagnostics | 9/98 | 4Q:98E | $1,100 | Bayer will pay $1.1B cash for Chiron's |
Corp. (subsidiary of | business of Bayer | in vitro diagnostics subsidiary; Bayer | |||
Chiron Corp.) | AG (Germany) | also gets semi-exclusive license to cer- | |||
tain of Chiron's patents on HCV and | |||||
HIV for use in nucleic acid diagnostics; | |||||
Chiron gets royalties on worldwide | |||||
sales; Chiron retains right to license | |||||
this technology to others or to use it | |||||
in-house; Chiron retains its 2 blood | |||||
testing businesses; transaction pending | |||||
approval of regulatory authorities | |||||
D-Pharm Ltd.* | The Clal Group and | 7/98 | — | $10 | Clal and D-Pharm signed a memoran- |
(Israel) | Clal Biotechnology | dum of understanding in which Clal | |||
Industries (Israel) | will acquire a 20% stake in D-Pharm | ||||
for $10M | |||||
DepoTech Corp. | SkyePharma plc | 10/98 | 1Q:99E | $55.7 | SkyePharma will acquire DepoTech in |
(U.K.) | a stock exchange and equity purchase | ||||
valued at $30.7M; SkyePharma will | |||||
offer 2.7M American Depositary | |||||
Shares (ADSs) for all DepoTech's out- | |||||
standing shares in ratio of 1.86 ADS | |||||
per 10 DepoTech shares; the companies | |||||
also formed a strategic alliance on drug | |||||
delivery technologies under which Skye- | |||||
Pharma paid $5M for 2.9M shares of Depo- | |||||
Tech ($1.75 each, a 40% premium to market); | |||||
the stock exchange and equity purchase | |||||
are valued at $30.7M; the purchase | |||||
price will increase by $14M in ADSs if | |||||
DepoCyt is launched in the U.S. by 3/31/00 | |||||
and by an additional $11M if DepoTech | |||||
signs a corporate partnership for Depo- | |||||
Morphine or a macromolecule by 3/00; | |||||
transaction requires approval by Depo- | |||||
Tech shareholders | |||||
GeneMedicine Inc. | Megabios Corp. | 10/98 | 1Q:99E | $38 | This merger will be accomplished by a |
stock exchange; each outstanding share | |||||
of GeneMedicine will be exchanged at | |||||
a ratio of 0.571 for newly issued shares | |||||
of Megabios; Megabios will issue 9.1M | |||||
new shares in all; Megabios will own | |||||
59% of new company (yet to be | |||||
named) and GeneMedicine will own | |||||
41%; all outstanding GeneMedicine | |||||
stock options will convert to Megabios | |||||
options at the same exchange ratio; | |||||
transaction subject to approval by | |||||
shareholders of both companies | |||||
Life Technologies | Dexter Corp. | 7/98 | — | $240 | Dexter has proposed acquiring the 48% |
Inc. | (NYSE:DEX) | of Life Technologies it doesn't already | |||
own (11.3M shares) through a tender | |||||
offer of $37.00 cash per share (19.4% | |||||
premium to market); on 10/27/98, a | |||||
committee of independent directors of | |||||
Life Technologies' board said it would | |||||
not recommend approval of this offer, | |||||
but on 11/2/98 Dexter initiated the ten- | |||||
der offer anyway; on 11/6/98, Life | |||||
Technologies filed a class action com- | |||||
plaint to stop consummation of the | |||||
tender offer | |||||
OST Developpment | Osteotech Inc. | 7/98 | 3/99E | $1.5 | Osteotech will acquire a majority inter- |
SA* (subsidiary of | est in OST in 2 steps; in 6/98, it acquired | ||||
Transphyto SA; France) | a 5% stake; it will acquire an addi- | ||||
tional 85% stake no later than 3/99, | |||||
contingent on certain milestones; total | |||||
cost will be $1.5M (FFr9M); the agree- | |||||
ment provides for Osteotech's purchase | |||||
of the remaining 10% in the future | |||||
Pacific | Procept Inc. | 11/98 | — | ND | Pacific Pharmaceuticals will merge into |
Pharmaceuticals Inc. | Procept; each Pacific Pharmaceuticals | ||||
(OTC Bulletin Board: | share will convert into 0.12 share of | ||||
PHAA) | Procept; Procept will also assume | ||||
$7.3M obligation of Pacific Pharma- | |||||
ceuticals subsidiary BG Development | |||||
Corp; Pacific Pharmaceuticals preferred | |||||
shareholders get certain contractual | |||||
rights in exchange for waiving liquida- | |||||
tion rights; subject to definitive agreement | |||||
Sequus | Alza Corp. | 10/98 | 4Q:98/ | $580 | Alza will acquire Sequus in a stock |
Pharmaceuticals Inc. | 1Q:99E | exchange of 0.4 share Alza for 1 share | |||
Sequus; transaction valued at $16.975 | |||||
per share for Sequus shareholders; | |||||
subject to approval of regulatory | |||||
authorities and Sequus shareholders | |||||
TheraTech Inc. | Watson Pharma- | 10/98 | 1Q:99E | $300 | Watson will acquire TheraTech in a |
ceuticals Inc. | stock exchange of between 0.26630 | ||||
(NYSE:WPI) | and 0.29598 share of Watson (depend- | ||||
ing on Watson's market price at the | |||||
time) for 1 share of TheraTech; Thera- | |||||
Tech shareholders will get 6% stake in | |||||
Watson; transaction subject to approval | |||||
by TheraTech stockholders | |||||
UroCor Inc. | Dianon Systems | 8/98 | — | ND | Dianon offered to acquire all outstand- |
Inc. | ing shares of UroCor for $7.50 per share | ||||
(50% premium to market), but UroCor | |||||
rejected the offer and adopted a poison | |||||
pill; Dianon intends to move forward | |||||
with the acquisition anyway | |||||
Vascular Genomics | Corvas Inter- | 7/97 | 7/00E | $13-$20 | Corvas has a 3-year option to acquire |
Inc.* | national Inc. | Vascular Genomics; it will make the | |||
purchase with new shares of Corvas | |||||
stock from $13M-$20M; the option | |||||
will be automatically triggered if | |||||
Corvas enters into a partnering agree- | |||||
ment having an equal value; if Corvas | |||||
elects not to exercise option, Vascular | |||||
Genomics may require it to buy 20% | |||||
of its stock for $3.96M in Corvas stock | |||||
III. TERMINATED MERGERS AND ACQUISITIONS | |||||
Gen Trak Inc.* | Genetic Vectors | 5/98 | Termi- | Genetic Vectors was to have acquired | |
Inc. (OTC Bulletin | nated | 100% of Gen Trak's stock, but the for- | |||
Board:GVEC) | 8/98 | mer terminated the letter of intent when | |||
the companies were not able to come | |||||
to terms | |||||
NOTES: | |||||
# This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquisitions of single products or of manufacturing facilities and plants. It does not include mergers and acquisitions in the area of agricultural biotechnology (which are treated separately in BioWorld Financial Watch). The information on the chart encompasses the period from 7/25/98 11/9/98. For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day of the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced. | |||||
E = Estimated date, dependent on approval of regulatory authorities and shareholders of one or all companies involved in the transaction; ND = Not disclosed, reported and/or available; TSE = Toronto Stock Exchange | |||||
* Private companies are indicated with an asterisk. | |||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 11-12. |